Document is current
Any future updates will be listed below
-
Authors
Grabein, Beatrice
Arhin, Francis F.
Daikos, George L.
Moore, Luke S. P.
Balaji, V.
Baillon-Plot, Nathalie
-
Funding
Funding for this research was provided by:
Pfizer
- License Information
-
More Information
Article History
Received: 23 July 2024
Accepted: 2 September 2024
First Online: 1 October 2024
Declarations
:
: Nathalie Baillon-Plot is an employee of Pfizer and holds stock/stock options. Francis F Arhin is a former employee of Pfizer and holds stock/stock options. Beatrice Grabein has consulted for or received speaker fees from Advanz Pharma, Gilead, Infectopharm, MSD, Mundipharma, Pfizer and Shionogi. Luke S P Moore has consulted for or received speaker fees from bioMerieux, Eumedica, Pfizer, Sumitovant, Shionogi, Qiagen, and Gilead, and receives academic support from the National Institute of Health Research (NIHR) CW + Charity, North West London Pathology, LifeArc, Shionogi, and the Healthcare Infection Society. George L Daikos and V Balaji have no conflicts of interest to declare.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
